We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Amgen Inc | NASDAQ:AMGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.82 | 0.27% | 300.30 | 300.00 | 301.75 | 302.91 | 298.51 | 301.75 | 2,452,225 | 01:00:00 |
From May 2021 to May 2024
By Colin Kellaher
Amgen Inc. on Monday said AstraZeneca PLC has filed for U.S. Food and Drug Administration approval of tezepelumab, a potential first-in-class medicine in severe asthma.
The Thousand Oaks, Calif., biotechnology company, which has been collaborating with U.K. pharmaceutical giant AstraZeneca on tezepelumab since 2012, said the filing is supported by results from a pivotal Phase 3 study that showed a statistically significant and clinically meaningful reduction in the annualized asthma exacerbation rate in patients with severe, uncontrolled asthma compared to placebo.
AstraZeneca leads the development of tezepelumab, while Amgen leads manufacturing of the drug. The companies plan to jointly commercialize tezepelumab in North America, with Amgen recording sales in the U.S. and AstraZeneca booking sales in Canada.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 10, 2021 09:45 ET (13:45 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Amgen Chart |
1 Month Amgen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
